118 related articles for article (PubMed ID: 24843527)
1. Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance.
Masuda K; Aoki K; Terauchi Y
J Diabetes Investig; 2011 Nov; 2(6):435-40. PubMed ID: 24843527
[TBL] [Abstract][Full Text] [Related]
2. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with type 2 diabetes treated with sitagliptin.
Aoki K; Kamiyama H; Yoshimura K; Shibuya M; Masuda K; Terauchi Y
Acta Diabetol; 2012 Jun; 49(3):225-30. PubMed ID: 21898126
[TBL] [Abstract][Full Text] [Related]
3. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
4. Comparison of efficacy and safety of taking miglitol dissolved in water during a meal and taking a miglitol tablet just before a meal in patients with type 2 diabetes.
Shibata E; Aoki K; Tajima K; Taguri M; Terauchi Y
Expert Opin Pharmacother; 2016; 17(7):889-94. PubMed ID: 26918556
[TBL] [Abstract][Full Text] [Related]
5. Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study.
Ueno H; Tsuchimochi W; Wang HW; Yamashita E; Tsubouchi C; Nagamine K; Sakoda H; Nakazato M
Diabetes Ther; 2015 Jun; 6(2):187-96. PubMed ID: 26055217
[TBL] [Abstract][Full Text] [Related]
6. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
7. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
Aoki K; Miyazaki T; Nagakura J; Orime K; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):673-7. PubMed ID: 20519807
[TBL] [Abstract][Full Text] [Related]
8. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men.
Aoki K; Masuda K; Miyazaki T; Togashi Y; Terauchi Y
Endocr J; 2010; 57(8):667-72. PubMed ID: 20519806
[TBL] [Abstract][Full Text] [Related]
9. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients.
Aoki K; Nakamura A; Ito S; Nezu U; Iwasaki T; Takahashi M; Kimura M; Terauchi Y
Diabetes Res Clin Pract; 2007 Oct; 78(1):30-3. PubMed ID: 17493703
[TBL] [Abstract][Full Text] [Related]
10. Effects of miglitol, vildagliptin, or their combination on serum insulin and peptide YY levels and plasma glucose, cholecystokinin, ghrelin, and obestatin levels.
Aoki K; Kamiyama H; Masuda K; Kamiko K; Noguchi Y; Tajima K; Terauchi Y
Endocr J; 2014; 61(3):249-56. PubMed ID: 24389993
[TBL] [Abstract][Full Text] [Related]
11. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men.
Aoki K; Kato H; Terauchi Y
Endocr J; 2007 Dec; 54(6):1009-14. PubMed ID: 18048991
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of antidiabetic alpha-glucosidase inhibitors: a review on the timing of administration and effects on gut hormones.
Aoki K; Sato H; Terauchi Y
Endocr J; 2019 May; 66(5):395-401. PubMed ID: 31019154
[TBL] [Abstract][Full Text] [Related]
13. Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects.
Frid AH; Nilsson M; Holst JJ; Björck IM
Am J Clin Nutr; 2005 Jul; 82(1):69-75. PubMed ID: 16002802
[TBL] [Abstract][Full Text] [Related]
14. Effect of the α-glucosidase inhibitor miglitol on the glucose profile in Japanese type 2 diabetic patients receiving multiple daily insulin injections.
Kato H; Ohta A; Kobayashi S; Ishii S; Sada Y; Kobayashi H; Ohmori S; Kondo A; Katabami T; Fuse J; Fukuda H; Nagai Y; Tanaka Y
Endocr J; 2012; 59(4):345-52. PubMed ID: 22301938
[TBL] [Abstract][Full Text] [Related]
15. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of vildagliptin combined with miglitol on glucose tolerance and islet morphology in diet-controlled db/db mice.
Ishibashi K; Hara A; Fujitani Y; Uchida T; Komiya K; Tamaki M; Abe H; Ogihara T; Kanazawa A; Kawamori R; Watada H
Biochem Biophys Res Commun; 2013 Nov; 440(4):570-5. PubMed ID: 24103756
[TBL] [Abstract][Full Text] [Related]
17. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
[TBL] [Abstract][Full Text] [Related]
18. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
Ono Y; Kamoshima H; Nakamura A; Nomoto H
Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
[TBL] [Abstract][Full Text] [Related]
19. Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes.
Kishimoto M; Noda M
Diabetes Ther; 2012 Nov; 3(1):11. PubMed ID: 23055336
[TBL] [Abstract][Full Text] [Related]
20. Mosapride citrate, a 5-HT₄ receptor agonist, increased the plasma active and total glucagon-like peptide-1 levels in non-diabetic men.
Aoki K; Kamiyama H; Masuda K; Togashi Y; Terauchi Y
Endocr J; 2013; 60(4):493-9. PubMed ID: 23257734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
